Dr Ilene Weitz reviews data on novel agents and their efficacy in enhancing quality of life and minimizing breakthrough events.

Updates in ER+ breast cancer from SABCS 2024 include the EMBER-3 trial of novel oral SERD imlunestrant, PATINA trial results, and updated analysis from TAILORx, as reported by Dr Harold Burstein.

Eighty percent of doctors in a Medscape survey answered no when asked, “Is enough known about obesity meds’ risk to ...

Experts propose potential workarounds for obstacles to wider use of combined clinics and personalized medicine for ...

Adults who were obese and exercised more than 150 min/wk at moderate intensity or higher experienced clinically important ...

The RSVpreF vaccine demonstrated 91% effectiveness against RSV-related lower respiratory tract disease in older adults during ...

Early antiretroviral therapy in children with perinatal HIV alleviated HIV-related lung function abnormalities and ...

Biomarker staging of liver fibrosis in hepatitis C was cost effective, but so was initiating treatment without testing.

TNF inhibitors offered greater protection against fractures than NSAIDs in patients with axial spondyloarthritis (axSpA).

Only about 1 in 6 internal medicine specialists believe their compensation is more important than workplace culture, ...

A study has shown that administering ≥ 2 L of crystalloids during the prehospital and emergency department phases of ...

Combined exposure to dioxins and dioxin-like polychlorinated biphenyls (DL-PCBs) is significantly associated with an ...